key: cord-0300088-bosx5p06
authors: Foguet, C.; Xu, Y.; Ritchie, S. C.; Lambert, S. A.; Persyn, E.; Nath, A. P.; Davenport, E. E.; Roberts, D. J.; Paul, D. S.; Di Angelantonio, E.; Danesh, J.; Butterworth, A. S.; Yau, C.; Inouye, M.
title: Genetically personalised organ-specific metabolic models in health and disease
date: 2022-03-31
journal: nan
DOI: 10.1101/2022.03.25.22272958
sha: e50a356b51790f774ae4d72c64fea71b31aebc43
doc_id: 300088
cord_uid: bosx5p06

Understanding how genetic variants influence disease risk and complex traits (variant-to-function) is one of the major challenges in human genetics. Here we present a model-driven framework to leverage human genome-scale metabolic networks to define how genetic variants affect biochemical reaction fluxes across major human tissues, including skeletal muscle, adipose, liver, brain and heart. As proof of concept, we build personalised organ-specific metabolic flux models for 524,615 individuals of the INTERVAL and UK Biobank cohorts and perform a fluxome-wide association study (FWAS) to identify 4,411 associations between personalised flux values and the concentration of metabolites in blood. Furthermore, we apply FWAS to identify 97 metabolic fluxes associated with the risk of developing coronary artery disease, many of which are linked to processes previously described to play in role in the disease. Our work demonstrates that genetically personalised metabolic models can elucidate the downstream effects of genetic variants on biochemical reactions involved in common human diseases.

Genome-wide association studies (GWAS) have identified more than 50,000 genetic variants associated with 40 complex traits or diseases 1 . While the contribution of individual variants to a given phenotype is generally 41 small, the effect of multiple genetic variants can be aggregated into polygenic scores (PGS), which are highly 42 predictive of disease incidence and enhance existing risk models 2-4 . However, while GWAS and PGS can be 43 useful for risk stratification 5-7 , the mechanisms by which genetic variants influence disease risk, i.e. variant 44 to function (V2F), remain largely unsolved. Addressing V2F is a major challenge in human genetics and has 45 the potential to unveil many new therapeutic targets 6,8,9 . 46 An approach to address the V2F challenge is to quantify how genetic variation causes disease through the 47 regulation of molecular traits. To this end, genetic variants affecting gene expression are identified and 48

subsequently aggregated into models that can impute the abundances of transcripts and proteins 10,11 . For 49 example, PredictDB is a database that offers a collection of linear models to impute transcript levels in 50 specific organs of the human body 12 . PredictDB models were trained in the GTEx dataset, which contains 51 genotype profiling and tissue-specific transcript abundance from post-mortem donors 13 . Imputed transcript 52 or protein levels can be used to perform transcriptome-wide or proteome-wide association analyses, 53 respectively, to identify gene products associated with disease 10,14 . Alternately, PGSs for disease can be used 54

to identify proteins and other gene products which may disrupt polygenic risk 15 . However, transcripts and 55

proteins do not exert their effects in isolation but in highly connected and complex biological networks. 56 Indeed, previous studies have shown the merit of analysing genetic variation in the context of gene co-57 expression and gene interaction networks to characterise how the effects of genetic variants contribute to 58 complex traits or disease by propagating through biological networks 16-19 59 Metabolism is one of the most prominent biological networks and a comparatively tractable experimental 60 setting in which to address the V2F challenge. Essentially, metabolism is a set of interconnected chemical 61 reactions and transport processes occurring in a highly ordered, regulated and coordinated manner across 62 multiple organs in the human body 20 . The metabolic phenotype of a given organ is defined by both metabolite 63 concentrations and metabolic fluxes (i.e. the rates at which substrates are converted to products through 64 reactions) and emerges from the complex interaction of metabolites, enzymes and transmembrane 65 carriers 21, 22 . Metabolite concentrations offer a static snapshot of metabolite distributions, whereas metabolic 66 fluxes provide a map of metabolite traffic through metabolic pathways 23 . 67

Genome-scale metabolic models (GSMMs), mathematical representations of the metabolic reaction network 68 arising from the human genome 24,25 , simulate steady-state metabolic fluxes by formulating network 69 stoichiometry as sets of linear equations and directionality constraints 26 . GSMMs have emerged as a useful 70 approach to integrate transcriptomics, proteomics, and metabolomics to characterise metabolic flux maps 27,28 . 71

For example, proteomics, metabolomics and physiological data have been used to build human organ-specific 72

GSMMs 29 . Similarly, there is increasing interest to integrate individual measures to build personalised 73

GSMMs that reflect the specific metabolic phenotype in each individual, thus facilitating personalised 74 medicine [29] [30] [31] [32] [33] . 75

Since gene expression is highly heritable 10,12 , it may be feasible to leverage human genome-scale metabolic 76 networks to analyse the system-wide effects of genetic variants on metabolism and build genetically 77

personalised GSMMs. To this end, we present a framework where transcript levels imputed from genetic 78 data can be used to simulate personalised and organ-specific, genome-scale flux maps using the quadratic 79 metabolic transformation algorithm (qMTA). Such flux maps provide genetically personalised metabolic 80 models at a genome scale for each tissue. As proof of concept, we build personalised organ-specific flux 81 maps for over 520,000 individuals across the INTERVAL 34,35 and UK Biobank (UKB) 36 cohorts, then 82 perform a fluxome-wide association study (FWAS) to test the association between organ-specific flux values 83 and directly measured blood metabolite levels. Finally, we apply FWAS to identify fluxes associated with 84 coronary artery disease (CAD), thus demonstrating the potential of genome-scale flux maps for V2F by 85 elucidating intermediary biochemical reactions between genetic variation and common disease. 86

A computational framework for genetically personalised organ-specific GSMMs 88

We developed a framework for building personalised organ-specific flux maps from genotype data ( Fig. 1;  89 Methods). The first step is to compute a reference flux distribution for each organ under consideration. This 90 is achieved by extracting the organ-specific subnetwork from the Harvey/Harvetta multiorgan model 29 , 91

defining organ-specific metabolic functions that must be fulfilled (e.g. synthesis of neurotransmitters in the 92 brain), obtaining average organ transcript abundance from GTEx 13 and using the transcript abundance as an 93

input for the GIM3E algorithm 37 . GIM3E is an algorithm that, subject to maintaining the organ-specific 94 metabolic functions, seeks to minimise the overall flux through the network using transcript abundance data 95

to give each reaction a minimisation weight inversely proportional to the expression of the enzymes 96 catalysing it. Subsequently, flux sampling 38 is applied to identify a representative solution within the solution 97

space and within 99% of the GIM3E optimal solution. The resulting set of flux values, termed reference flux 98 distribution, is both enzymatically efficient and consistent with the average transcript abundance in each 99 organ (Fig. S1 ). The flux distribution can be assumed to represent the average metabolic state of each 100 modelled organ in the sampled population. 101

Subsequently, models from PredictDB 12 are used to impute organ-specific transcript abundances from 102 genotype data. The resulting imputed transcript data are mapped to reactions in the organ-specific 103 subnetworks derived from the Harvey/Harvetta multiorgan model 29 as putative reaction activity fold changes 104 relative to the average organ-specific transcript expression in GTEx 13 . The imputed reaction activity fold 105 changes and the reference flux distributions are then utilised by the qMTA to compute genetically 106 personalised organ-specific flux maps (Fig. S2) . Briefly, qMTA finds the flux distributions (i.e., sets of flux 107 values) most consistent with the putative reaction activity fold changes in each individual (Methods). 108 S3). As such, from the 16,058 reaction flux values, we selected a subset of 4,418 flux values without strong 117 pairwise correlations (ρ<0.9) for further analysis ( Fig. S4; Methods) . 118   Principal component analysis of the personalised organ-specific flux values for individuals of INTERVAL  119 and UKB showed the underlying structure in the data (Fig. S5) . Fluxes with the greatest loadings on top 120

principal components (PCs) tended to be related to the known metabolism of each organ (Table S1) . For 121 example, in the liver, fluxes through reactions and transport processes of amino acid and lipid metabolism 122 exhibited large loadings along the first five PCs. These included reactions linked to urea and acetaldehyde, 123

which are predominantly metabolised in the liver 20,40 . Similarly, in skeletal muscle and heart, fluxes through 124 transport processes of amino acid metabolism and reactions of fatty acid metabolism also had large PC 125

loadings. However, in the heart, PC4 was also strongly associated with the flux through several reactions 126 linked to the antioxidant defence system, which is associated with heart failure 41 . In the brain, PC1, PC2 and 127 PC5 were strongly related to fluxes through reactions and transport processes of amino acid metabolism, 128

including reactions linked to neurotransmitters such as dopamine, serotonin, or norepinephrine. However, 129

PC3 was also strongly associated with fluxes linked to glycolipid metabolism, including gangliosides, a class 130 of sialylated glycosphingolipids that predominate in nerve cells 42 . Finally, in adipose tissue, most PCs were 131 associated with fluxes linked with lipid metabolism, such as the malic enzyme, which has a key role in de 132

novo fatty acid synthesis 43 . 133 134 Fig. 1 : Framework for computing organ-specific personalised genome-scale flux maps from genotype 135 data and performing a fluxome-wide association study (FWAS). First, a reference flux map is computed 136

for each organ using the GIM3E algorithm to integrate average transcript abundances and organ-specific 137 metabolic functions into an organ-specific metabolic subnetwork. In parallel, personalised organ-specific 138 . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint .  156 2A-2B). Consistent with the role of liver in whole-body metabolic homeostasis 20 , liver was the organ with 157 the most associations (1,588), followed by heart (1,098), skeletal muscle (792), brain (536) and adipose tissue 158 (397) (Fig. 2C , Table S2 ). 159

We externally validated the INTERVAL flux associations with Nightingale metabolites using UKB (Fig.  160 2D). We found 83% of the INTERVAL associations replicated in UKB with FDR-adjusted significance 161 threshold of P<1.0x10 -6 and consistent direction of the effect sizes. Effect sizes were themselves highly 162 correlated (ρ=0.82) between INTERVAL and UKB (Fig. S6 ). 163

Fluxome associations by metabolic feature class and reaction subsystem 164

The 4,411 significant associations comprised 224 unique blood metabolic features and 649 unique organ-165 specific metabolic fluxes. Consistent with the coverage of the Nightingale Health and Metabolon HD4 166 platforms, we found that most of these blood metabolic features were lipid-related (Fig. 3A is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 31, 2022. ; https://doi.org/10.1101/2022.03.25.22272958 doi: medRxiv preprint brain and adipose tissue relative to all analysed reactions in each organ-specific metabolic network. In the 188 liver, reactions of glyceride and phospholipid metabolism and vitamin A metabolism were enriched. 189

There was widespread consistency between biochemical pathways and blood metabolic feature classes (Fig. 190 3C, Table S2 ). For example, reactions from the glycerides and phospholipids subsystem were primarily 191 associated with blood metabolic features of glycerides and phospholipids as well as lipoprotein fractions and 192 their constituents 20 . We found that reactions of fatty acid metabolism were primarily associated with blood 193 glyceride and phospholipids followed by lipoprotein fractions and fatty acids, which themselves provide acyl 194 chains to glycerides and phospholipids. Similarly, reactions from nucleotide metabolism and amino acid 195 metabolism were primarily associated with blood metabolic features of nucleotides and amino acids, 196

respectively. 197

Fluxes of the hepatic triacylglycerol to cholesteryl ester pathway and blood lipoproteins 198

In the liver, we identified 800 associations between fluxes and lipoprotein fractions ( Table S2 ). Many of 199 these associations were to reactions of glycerides and phospholipids metabolism as well as vitamin A 200 metabolism, which were enriched in associations relative to all analysed liver fluxes (Methods; Fig. 3B ).

FWAS revealed that a major determinant of triacylglycerols (TAG), free cholesterol (FC), and cholesteryl 202 esters (CE) fractions in lipoproteins was a sequential set of reactions which we term the TAG to cholesterol 203 esterification (TAG-CE) pathway (Fig. 4) . In the TAG-CE pathway, TAGs are hydrolysed to diglycerides 204 and fatty acids in the liver, diacylglycerides are then used as a substrate to synthesise phospholipids (e.g. 205 phosphatidylcholine and phosphatidylethanolamine) which are subsequently used as substrates to esterify 206 FC. We found that fluxes through reactions of the TAG-CE pathway were strongly associated with an 207 increased percentage of CE in HDL and decreased TAG levels in LDL and HDL ( Table 1, Table S3 ). The 208 pathway was also strongly associated with reduced HDL size, likely driven by a reduction of TAG levels in 209 HDL 47 . While the associations were primarily found to the liver-specific flux map with mediation by liver-210 expressed enzymes, these pathways are not necessarily constrained to the liver. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 31, 2022. ; https://doi.org/10.1101/2022.03.25.22272958 doi: medRxiv preprint denote the number of significant associations between reaction fluxes of a given subsystem and blood 231 metabolic features of a given class. The colour key denotes the fraction of reactions of each subsystem in 232 each intersection. 233

Conversely, flux through reactions disrupting TAG-CE, such as cholesterol esterase or alternative sources of 234 free fatty acids which lower the flux through triglyceride lipase, are predicted by our FWAS to have the 235 opposite effect and are associated with increased TAG levels and decreased cholesterol esterification (Table  236 1, Table S3 ). Some of these reactions are related to retinol metabolism (i.e. vitamin A metabolism) as retinols 237

can be esterified by Lecithin Retinol Acyltransferase (LRAT) competing for phospholipids with LCAT, and 238 esterified retinol can act as an alternative source of free fatty acids, thus inhibiting TAG lipase activity (Fig.  239  4) . Notably, administration of high doses of retinol derivatives has been reported to increase total triglyceride 240 levels and, in some instances, increase total cholesterol in LDL while decreasing total cholesterol in HDL 58-241 61 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint FWAS identifies metabolic fluxes associated with coronary artery disease 259 We extended our approach of fluxome-wide analysis to common disease and performed a multi-tissue FWAS 260

for coronary artery disease (CAD) in UK Biobank. We associated the 4,418 metabolic fluxes with CAD using 261 . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 31, 2022.

a Cox model (Methods), which identified 97 significant associations (FDR-adjusted P<0.05 controlling for 262 all tested fluxes). Liver fluxes yielded the largest number of significant associations with CAD (N=46), 263 followed by fluxes of adipose tissue (21), brain (12), heart (10) and skeletal muscle (8) (Fig. 5 ; Table S4 ). 264

Notably, the strongest association with CAD was the flux of the transport of norepinephrine in the brain with 265 a hazard ratio (HR) per s.d. of log-transformed flux value of 1.060 and a P value of 1.9x10 -23 (Table S4) . 266

Norepinephrine is a neurotransmitter that can increase blood pressure and may play a role in 267 atherosclerosis 63 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint 

Here we present a new framework that uses metabolic modelling to leverage the stoichiometric relationships 309 of enzymes in human genome-scale metabolic networks to characterise how genetic variants affect metabolic 310 phenotypes. We achieve this by integrating genetic effects on transcript levels into organ-specific GSMMs 311 and simulating how they propagate and interact into genome-scale flux maps of major human organs. To 312 validate our method, we built organ-specific models for adipose tissue, brain, heart, liver and skeletal muscle 313 for over 520,000 individuals from the INTERVAL 34,35 and UKB 36 cohorts, increasing by more than two 314 orders of magnitude the number of personalised GSMMs built in previous works 29-32 . Association analyses 315

were performed between genetically-personalised flux values and directly measured blood metabolites in 316 both INTERVAL and UKB, identifying many significant and replicable associations. As expected, we found 317 that most blood metabolic features were associated with functionally related flux pathways. Finally, we 318 demonstrate that fluxome-wide analysis can be used to identify putative metabolic drivers of coronary artery 319 disease. 320

With cardiovascular disease a leading cause of mortality and comorbidity worldwide, the identification of 321 specific biochemical reactions using population-scale genomic data is of significant interest to both basic 322 discovery science and the development of therapeutics 86 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint As a proof of concept, this study focused on modelling five of the most prominent human organs 39 . Given 328 the increasing availability of models to impute tissue-or cell-specific transcript abundance from genotype 12 , 329 this approach may be expanded to other tissues and cell types. We envision that future applications may also 330 select organs for modelling based on the target disease(s). Similarly, the modelling framework could also be 331 expanded to include additional layers of data such as imputed protein abundance 14 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The Metabolon HD4 assay measures ~1000 metabolites (~700 named, ~300 unknown), including lipids, 367 xenobiotics, amino acids and energy-related metabolites. Nineteen features were excluded due to a large 368 number of NA(>75%). Values were regressed against technical covariates age, sex, BMI, and the first 5 PCs 369 of genetic ancestry. Subsequently, measures were standardised to zero-mean and unit-variance. 370

Building organ-specific reference flux maps 371

For each analysed organ (i.e., adipose tissue, brain, liver, heart and skeletal muscle), the organ-specific 372 genome-scale metabolic network was extracted from the Harvey/Harvetta metabolic reconstructions 29 . To 373 avoid any gender biases, any reaction present in either the male (Harvey) or female (Harvetta) models was 374 included, and the reaction flux boundaries for exchange reactions were established as the average between 375 both models. Metabolites in blood or bile ducts were made boundary conditions (i.e., assumed constant), 376

allowing each organ subnetwork to function independently. Lastly, networks were manually tuned to ensure 377 that the resulting flux maps were biologically relevant and that each organ could adequately fulfil its basic 378 metabolic functions. The process involved modifying the constraints of exchange reactions so that the ranges 379 of metabolite uptake and secretion of each organ were physiologically feasible, filling gaps in the pathways 380 of fatty acid metabolism and removing artificial sink reactions. Additionally, the artificial metabolites Rtotal, 381 used to simulate the side acyl chains of triacylglycerides in the RECON family of GSMMs 25 , were substituted 382 by a stoichiometric mix of 1/3 oleic acid, 1/6 palmitoleic acid, 1/6 palmitic acid, 1/6 stearic acid and 1/6 383 myristic acid. This was necessary to ensure that mass was conserved while allowing both novo-synthesis and 384 degradation of triacylglycerols. The resulting metabolic networks are available at 385 https://github.com/cfoguet/cobrafunctions/tree/main/example_inputs/organ_specific_models. 386

Next, a set of metabolic requirements were defined for each organ representing metabolic functions that each 387 organ fulfils in physiological conditions (Table S5) . These were added in each organ subnetwork as lower 388 bounds for flux values through reactions associated with those metabolic requirements. Lower bounds were 389 set relative to the maximum flux feasible through such reactions identified with flux variability 390 analysis(FVA) 94 . In addition, all organs were also constrained to be able to maintain their biomass (i.e., to be 391 able to synthesise structural lipids, proteins, and nucleotides to counter their natural decay). 392

Organ-specific transcript abundances were obtained as Transcripts Per Million (TPM) from the GTEx 393

Portal 13 on 05/05/2021 (GTEx Analysis Release V8; dbGaP Accession phs000424.v8.p2) and the average 394 abundance of each transcript in each organ was obtained. In the heart, adipose tissue, and brain, there were 395 transcripts abundances measured from multiple source sites. Clustering analysis indicated that samples from 396 each organ source site were clustered together (Fig. S7) . Hence, the average of all sample source sites was 397 used for heart, adipose tissue and brain tissue. 398

Average transcript abundances were mapped to the organ-specific subnetworks using the gene reaction 399

annotations of Harvey/Harvetta 29 . More in detail, transcript abundances of isoenzymes and enzymes subunits 400 catalysing each reaction or transport process were added and, subsequently, log2 transformed. The resulting 401

values were used as input to apply the GIM3E algorithm 37 . The GIM3E algorithm applies a flux minimisation 402 weighted by transcript abundance allowing to identify solutions that are both enzymatically efficient and 403 consistent with gene expression data (Fig. S1) . 404 . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint adipose, brain and heart tissue, the average of the imputed abundances in each source site were used. 427

Mapping individual-specific gene expression data to reactions in the model 428

Imputed individual-specific expression patterns from metabolic genes (i.e., genes coding for enzymes, 429 enzyme subunits, or transmembrane carriers) were mapped to organ-specific models using the gene reaction 430

annotations of Harvey/Harvetta 29 . Imputed values were expressed as log2 fold changes relative to average 431 gene expression in GTEx. Imputed fold changes were then mapped to reactions in the organ-specific model 432

considering the relative transcript abundance of isoenzymes and enzyme subunits in GTEx: 433

where, 435

, is the organ-specific score for gene g in individual z computed using the elastic nets models from 436

PredictDB; is the average organ-specific gene expression in GTEx of gene g; are the genes 437 associated with reaction R in the organ-specific network; , is the imputed reaction activity fold change 438

for reaction R in individual z. 439 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint (w→[100,10,1,0.1,0.01], m→ [10 -6 , 10 -7 , 10 -8 , 10 -9 , 10 -10 , 10 -11 , 10 -12 ]) was performed to identify the 463 parameters that resulted in flux maps with the strongest association with both Nightingale Health and 464

Metabolon HD4 metabolic features. This was measured as the summation of the amount of variance 465 explained (R 2 ) for each pair of blood metabolic feature and flux value when testing associations between 466 metabolic fluxes and blood metabolic features. The resulting parameters were subsequently used in the 467 analysis of the samples from UKB. 468

Testing associations between metabolic fluxes and blood metabolic features 469

Due to the linear nature of many metabolic pathways, some flux values were highly intercorrelated (Fig S3- is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Then, the association of each metabolic feature to each personalised flux value was evaluated using a linear 477 regression (Equation 4;Fig. S2 ). Nightingale/Metabolon platforms provide sets of Groups/Sub pathways to stratify metabolic features. We 489 harmonised both annotations systems to define a set of curated groups that could be applied to both 490

Nightingale and Metabolon features (Table S6) . For instance, the Metabolon features annotated to 491 "Glycerolipid Metabolism" and "phospholipid metabolism", and the Nightingale features annotated to 492

"phospholipids" were all reassigned to the curated group "Glycerides and phospholipids". Some Metabolon 493 features were not annotated (i.e., unknown) and could not be assigned to any curated group. Unknown 494 features were included in the FWAS but omitted from enrichment analysis. Fisher's exact test was used to 495 identify metabolite classes enriched in features with significant association to personalised flux values 496 relative to the set of all uncorrelated blood metabolic features. An FDR-adjusted significance threshold of 497 P<0.05 was applied to control for all tested classes of blood metabolic features across all organs. 498 499 Reaction subsystems 500

Subsystem annotations for reactions were obtained from the Harvey/Harvetta model 29 . As some subsystems 501 either contained an excessively low number of reactions or had reactions that functionally could be 502 considered to belong to several subsystems, similar subsystems were aggregated into large ones. For instance, 503 pyrimidine synthesis, purine synthesis, pyrimidine catabolism, purine catabolism and nucleotide 504 interconversion were aggregated into a subsystem termed nucleotide metabolism. Additionally, reactions 505 from transport subsystems were reassigned to the reaction subsystem most frequent in the metabolites being 506

transported (e.g., transport of palmitate across the extracellular membrane was reassigned from "Transport, 507 extracellular" to "Fatty acid metabolism") ( Table S7) . Fisher's exact test was used to identify subsystems 508 enriched in reactions with significant association with blood metabolic features relative to the set of all 509 evaluated reactions in a given organ. An FDR-adjusted significance threshold of P<0.05 was applied to 510 control for all tested subsystems across all organs. 511

. CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint (ICD) diagnosis codes in versions 9 (ICD-9) and 10 (ICD-10) of Phecode 411.1 for CAD case definition in 515 UKB. In detail, we searched for the presence of any of the constituent ICD-9/10 codes in linked health records 516

(including in-patient Hospital Episode Statistics data, and primary and secondary cause of death information 517 from the death registry), and converted the earliest coded date to the age of phenotype onset. Individuals 518 without any codes for the phenotype of interest were recorded as controls and censored according to the 519 maximum follow-up of the health linkage data (January 31, 2020) or the date of death. Thus, to define the 520 cohort for testing flux associations with the age-of-onset of CAD, we used the set of events and censored 521 individuals described above. 522

Association was evaluated using the age-as-time-scale Cox proportional hazards regression. The Cox models 523

were stratified by sex and adjusted by genotyping array, 10 genetic PCs, BMI and smoking status. The Cox 524 model was fitted using the CoxPHFitter function from the lifelines package for python 100 . 525

The workflow to build personalised organ-specific flux maps from imputed gene expression data uses 527 custom-built functions and scripts implemented in the framework of COBRA for python(COBRApy) 95 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint network with three reactions and one ramification is provided, and a hypothetical feasible space is shown on 563 a 3D space. Next, a set of organ-specific metabolic functions are defined, and the solution space is constrained 564 to only solutions above a given threshold (lbobj) for these objectives. Next, a vector of minimisation weights 565 (w) for reactions is defined using average transcript abundances from GTEx mapped to reactions of the organ-566 specific network (x̄GTEx). P95 is the 95 th percentile of the average transcript abundance values mapped to 567 reactions of the organ-specific network. Next, the GIM3E algorithm is used to perform a weighted 568 minimisation of total reaction fluxes. Finally, the vicinity of the GIM3E solution space is defined and sampled 569

to obtain a representative flux map. ThGIM3E is the maximum value of the GIM3E objective used to define the 570 vicinity of the GIM3E solution space. 571 Methods. The resulting personalised flux values can be used to perform FWAS to complex traits or diseases. 580

As part of this process, a given trait is independently regressed against the fluxes through each reaction in the 581 network to test for association. For instance, to perform FWAS on blood metabolome, the measure of each 582 metabolite will be linearly regressed against the flux through each reaction in a given organ metabolic 583

network. Blood metabolic features can include the concentration of metabolites (e.g., [Glc]: Glucose 584 concentration), the concentration of metabolite fractions in lipoproteins (e.g.

[LDL_TG]: Triglycerides in 585 LDL) and ratios and relative measures (e.g., %: degree of fatty acid unsaturation). 586 . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 31, 2022. ; organs. The ten flux values with the most contribution to the first five principal components are indicated. 608

Each organ is analysed independently. 609 Table S4 : FWAS to coronary artery disease. Table detailing the 97 genetically personalised flux values  618 with significant associations to coronary artery disease risk in the UK Biobank cohort. 619 Table S5 : Metabolic requirements of each organ. 620 Table S6 : Annotations for blood metabolic features in the Nightingale and Metabolon platforms. 621

Nightingale/Metabolon platforms each provide sets of Groups/Sub pathways to stratify metabolic features. 622

Both annotations systems were harmonised to define a set of curated groups that could be applied to both 623

Nightingale and Metabolon features. 624 . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 31, 2022. ; https://doi.org/10.1101/2022.03.25.22272958 doi: medRxiv preprint

Benefits and limitations of genome-wide association studies

The Polygenic Score Catalog as an open database for reproducibility and 631 systematic evaluation

Improving reporting standards for polygenic scores in risk prediction studies

Polygenic Risk Score Task Force of the International Common Disease Alliance. Responsible use of 635 polygenic risk scores in the clinic: potential benefits, risks and gaps

The rise of the genome and personalised medicine

Drug development in the era of precision medicine

Towards clinical utility of polygenic risk scores

In The Blood: Connecting Variant to Function In 644 Human Hematopoiesis

Gaining insight into metabolic diseases from human genetic 646 discoveries

Opportunities and challenges for transcriptome-wide association studies

PWAS: proteome-wide association study-linking genes and 650 phenotypes by functional variation in proteins

A gene-based association method for mapping traits using reference 652 transcriptome data

GTEx Consortium. The Genotype-Tissue Expression (GTEx) project

Brain proteome-wide association study implicates novel proteins in depression 655 pathogenesis

Integrative analysis of the plasma proteome and polygenic risk of cardiometabolic 657 diseases

Modeling regulatory network topology improves genome-wide 659 analyses of complex human traits

A Fast and Flexible Framework for Network-Assisted Genomic Association

Cross-Tissue Regulatory Gene Networks in Coronary Artery Disease

between key biological processes and coronary artery disease

Metabolic Regulation: A Human Perspective

Metabolic fluxes and metabolic engineering

It is all about metabolic fluxes

Defining the metabolome: size, flux, and regulation

Global reconstruction of the human metabolic network based on genomic and 673 bibliomic data

Recon3D enables a three-dimensional view of gene variation in human metabolism

What is flux balance analysis?

Cancer cell metabolism as new targets for novel designed therapies

A benchmark-681 driven approach to reconstruct metabolic networks for studying cancer metabolism

Personalized whole-body models integrate metabolism, physiology, and the gut 684 microbiome

Reconstruction of genome-scale active metabolic networks for 69 human cell types 686 and 16 cancer types using INIT

Predicting selective drug targets in cancer through metabolic networks

Scale Metabolic Models Identify Targets of Redox Metabolism in Radiation-Resistant Tumors

Genome-Scale Metabolic Modeling of the 693

Human Microbiome in the Era of Personalized Medicine

The INTERVAL trial to determine whether intervals between blood donations can be 695 safely and acceptably decreased to optimise blood supply: study protocol for a randomised controlled 696 trial

Efficiency and safety of varying the frequency of whole blood donation 698 (INTERVAL): a randomised trial of 45 000 donors

UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range 701 of Complex Diseases of Middle and Old Age

GIM3E: condition-specific models of cellular metabolism developed from 703 metabolomics and expression data

An Improved Tool for Uniformly 705 Sampling the Solution-Space of Genome-Scale Metabolic Networks

Body Composition

Acetaldehyde adducts in alcoholic liver disease

Treating oxidative stress in heart 711 failure: past, present and future

Gangliosides of the Vertebrate Nervous System

Malic enzyme tracers reveal hypoxia-induced switch in adipocyte NADPH pathway 714 usage

A cross-platform approach identifies genetic regulators of human metabolism and 716 health

Metabolic biomarker profiling for 718 identification of susceptibility to severe pneumonia and COVID-19 in the general population

Steroid biosynthesis in adipose tissue

The metabolism and anti-atherogenic 723 properties of HDL

Hepatic lipase, 725 lipoprotein metabolism, and atherogenesis

Lecithin: cholesterol 727 acyltransferase--from biochemistry to role in cardiovascular disease

Hepatic lipase deficiency

Polymorphisms in the hepatic lipase gene affect 732 plasma HDL-cholesterol levels in a Turkish population

The C-480T hepatic lipase polymorphism is associated with HDL-C but not with 734 risk of coronary heart disease

Mouse Models of Diet-Induced Nonalcoholic Steatohepatitis Reproduce the 736 Heterogeneity of the Human Disease

OneDrive/post-doc/Cambridge/Literature/metabolism/liver tags and CE/HDL phospholipid 739 content and cholesterol efflux capacity are reduced in patients with very high HDL-C and coronary 740 disease.pdf

Encyclopedia of Endocrine 744 Diseases

Cholesterol is Inefficiently Converted to Cholesteryl Esters in the Blood of 746 Cardiovascular Disease Patients

Serum triglyceride elevation following high-dose vitamin 748 A treatment for pityriasis rubra pilaris

A sequential comparison of etretinate 750 (Tigason) and isotretinoin (Roaccutane) with special regard to their effects on serum lipoproteins. Br. 751

Changes in plasma lipids and lipoproteins during isotretinoin therapy for acne

Effect of long-term beta-carotene and vitamin A on serum cholesterol and 755 triglyceride levels among participants in the Carotene and Retinol Efficacy Trial (CARET)

Characterization and 758 properties of pre beta-HDL particles formed by ABCA1-mediated cellular lipid efflux to apoA-I

A possible role of catecholamines 761 in atherogenesis and subsequent complications of atherosclerosis

The hemodynamic effects of norepinephrine: far more than an increase in 763 blood pressure! Ann

Molecular regulation of histamine synthesis

In Patients With Obesity, the Number of Adipose Tissue Mast Cells Is 767 Significantly Lower in Subjects With Type 2 Diabetes

The emerging role of mast cells in liver disease

Blood histamine is associated with coronary artery disease, cardiac events and severity 771 of inflammation and atherosclerosis

An immune response network associated with blood lipid levels

Metabonomic, transcriptomic, and genomic variation of a population cohort

Histamine deficiency decreases atherosclerosis and inflammatory response in 777 apolipoprotein e knockout mice independently of serum cholesterol level

The pivotal role of lipoprotein lipase in atherosclerosis

PharmGKB very important pharmacogene: 782 SLCO1B1

Safety and efficacy of statin therapy

The eicosapentaenoic acid:arachidonic acid ratio and its clinical utility in 786 cardiovascular disease

The associations of plasma phospholipid arachidonic acid 788 with cardiovascular diseases: A Mendelian randomization study

The association of bile acid excretion and atherosclerotic coronary artery disease

Intake of individual saturated fatty acids and risk of coronary heart disease in US men 792 and women: two prospective longitudinal cohort studies

Serum fatty acid and risk of coronary artery disease -Circulatory risk in 794 communities study (CIRCS)

Identification of long and very long chain fatty acids, plasmalogen-C16:0 and 796 phytanic acid as new lipid biomarkers in Tunisian coronary artery disease patients

Circulating and dietary omega-3 and omega-6 polyunsaturated fatty acids 799 and incidence of CVD in the Multi-Ethnic Study of

Analyses of Group III Secreted Phospholipase A2 Transgenic Mice Reveal Potential 802 Participation of This Enzyme in Plasma Lipoprotein Modification, Macrophage Foam Cell Formation, 803 and Atherosclerosis

Phospholipase A2 enzymes and the risk of atherosclerosis

Discovery of AZD2716: A Novel Secreted Phospholipase A2 (sPLA2) Inhibitor 807 for the Treatment of Coronary Artery Disease

Group IIA Secretory Phospholipase A2, Vascular Inflammation, and Incident 809 Cardiovascular Disease: An Analysis from the JUPITER Trial

Hospital burden of coronary artery disease: 812 Trends of myocardial infarction and/or percutaneous coronary interventions in France

815 Triglycerides and cardiovascular risk

Systems biology of SNPs

Genome scale metabolic models as tools for drug design and personalized 818 medicine

Identification of anticancer drugs for hepatocellular carcinoma through personalized 820 genome-scale metabolic modeling

Model-based identification of drug targets that revert 822 disrupted metabolism and its application to ageing

The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common 824

Quality control and removal of technical variation of NMR metabolic biomarker 826 data in ~120,000 UK Biobank participants

Computationally efficient flux variability analysis

COnstraints-Based 830 Reconstruction and Analysis for Python

Creation and analysis of biochemical constraint-based models using the COBRA 832 Toolbox v.3.0

Second-generation PLINK: rising to the challenge of larger and richer datasets

Robust Metabolic 836 Transformation Analysis

Building Predictive Models in R Using the caret Package

lifelines: survival analysis in Python